Current and historical daily PE Ratio for FibroGen Inc (
) from 2018 to May 05 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. FibroGen stock (LTS:0IL8) PE ratio as of May 05 2024 is 0.
More Details
FibroGen Inc (LTS:0IL8) PE Ratio (TTM) Chart
FibroGen Inc (LTS:0IL8) PE Ratio (TTM) Historical Data
View and export this data going back to 2018. Start your Free Trial
Total 1264
- 1
- 2
- 3
- 4
- 5
- 6
- 15
| FibroGen PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-05 | At Loss | 2024-03-01 | At Loss |
| 2024-05-03 | At Loss | 2024-02-29 | At Loss |
| 2024-05-02 | At Loss | 2024-02-28 | At Loss |
| 2024-05-01 | At Loss | 2024-02-27 | At Loss |
| 2024-04-30 | At Loss | 2024-02-26 | At Loss |
| 2024-04-29 | At Loss | 2024-02-23 | At Loss |
| 2024-04-26 | At Loss | 2024-02-22 | At Loss |
| 2024-04-25 | At Loss | 2024-02-21 | At Loss |
| 2024-04-24 | At Loss | 2024-02-20 | At Loss |
| 2024-04-23 | At Loss | 2024-02-19 | At Loss |
| 2024-04-22 | At Loss | 2024-02-16 | At Loss |
| 2024-04-19 | At Loss | 2024-02-15 | At Loss |
| 2024-04-18 | At Loss | 2024-02-14 | At Loss |
| 2024-04-17 | At Loss | 2024-02-13 | At Loss |
| 2024-04-16 | At Loss | 2024-02-12 | At Loss |
| 2024-04-15 | At Loss | 2024-02-09 | At Loss |
| 2024-04-12 | At Loss | 2024-02-08 | At Loss |
| 2024-04-11 | At Loss | 2024-02-07 | At Loss |
| 2024-04-10 | At Loss | 2024-02-06 | At Loss |
| 2024-04-09 | At Loss | 2024-02-05 | At Loss |
| 2024-04-08 | At Loss | 2024-02-02 | At Loss |
| 2024-04-05 | At Loss | 2024-02-01 | At Loss |
| 2024-04-04 | At Loss | 2024-01-31 | At Loss |
| 2024-04-03 | At Loss | 2024-01-30 | At Loss |
| 2024-04-02 | At Loss | 2024-01-29 | At Loss |
| 2024-03-29 | At Loss | 2024-01-26 | At Loss |
| 2024-03-28 | At Loss | 2024-01-25 | At Loss |
| 2024-03-27 | At Loss | 2024-01-24 | At Loss |
| 2024-03-26 | At Loss | 2024-01-23 | At Loss |
| 2024-03-25 | At Loss | 2024-01-22 | At Loss |
| 2024-03-22 | At Loss | 2024-01-19 | At Loss |
| 2024-03-21 | At Loss | 2024-01-18 | At Loss |
| 2024-03-20 | At Loss | 2024-01-17 | At Loss |
| 2024-03-19 | At Loss | 2024-01-16 | At Loss |
| 2024-03-18 | At Loss | 2024-01-15 | At Loss |
| 2024-03-15 | At Loss | 2024-01-12 | At Loss |
| 2024-03-14 | At Loss | 2024-01-11 | At Loss |
| 2024-03-13 | At Loss | 2024-01-10 | At Loss |
| 2024-03-12 | At Loss | 2024-01-09 | At Loss |
| 2024-03-11 | At Loss | 2024-01-08 | At Loss |
| 2024-03-08 | At Loss | 2024-01-05 | At Loss |
| 2024-03-07 | At Loss | 2024-01-04 | At Loss |
| 2024-03-06 | At Loss | 2024-01-03 | At Loss |
| 2024-03-05 | At Loss | 2024-01-02 | At Loss |
| 2024-03-04 | At Loss | 2024-01-01 | At Loss |
FibroGen Inc (LTS:0IL8) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
FibroGen Inc
NAICS : 325412
SIC : 2834
ISIN : US31572Q8087
Compare
Compare
Traded in other countries / regions
FGEN.USA1FG.GermanyFGEN.Mexico0IL8.UK IPO Date
2018-01-25Description
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers